Orphan Exclusivity in the Reformed EU Framework: Nine Years, Eleven Years or Four

The reform of EU pharmaceutical law reshapes market exclusivity for orphan medicines. Published analyses of the final compromise describe a modulated system in place of the current uniform period.

The reported periods

Law firm summaries report a standard orphan market exclusivity of nine years, an extended period of eleven years for breakthrough products where no EU-authorised medicine exists for the condition and the product offers a clinically relevant reduction in morbidity or mortality, and a shorter period of four years for products relying on the well-established use pathway.

A change of architecture

The new Regulation repeals Regulation (EC) No 141/2000, so orphan rules are absorbed into the general framework. Reporting indicates that new exclusivity periods apply to orphan products whose applications are submitted after the Regulation applies, which is expected around late 2028. An EMA register for orphan medicines is also foreseen.

Why the distinction matters

  • Valuation. Modulated exclusivity changes the revenue horizon for rare disease assets.
  • Evidence strategy. Demonstrating a clinically relevant benefit over existing options becomes more valuable.
  • Competition. Existing orphan products retain their current protection, while new entrants face different expectations.

Interaction with market access

Longer exclusivity does not guarantee reimbursement. For rare diseases, joint clinical assessment will apply to orphan medicines from 2028 under the HTA Regulation, so regulatory and HTA planning for such products should be integrated.

How PQRA helps

PQRA supports rare disease sponsors with designation and maintenance strategy, protocol assistance planning, and the integration of regulatory timelines with HTA and Greek access preparation.

Contact PQRA to discuss your situation

CATEGORIES:

Uncategorized

Tags:

No responses yet

Αφήστε μια απάντηση

Η ηλ. διεύθυνση σας δεν δημοσιεύεται. Τα υποχρεωτικά πεδία σημειώνονται με *